What Dalsan Treats: Main Uses and Benefits

Dalsan is commonly used in clinical settings that involve acute or unstable symptom patterns, relevant when supportive symptom management is appropriate. It is primarily applied in contexts where symptoms that interfere with daily functioning create noticeable physiological strain.

This medicine is used to help with Major Depressive Disorder (MDD). It is also applicable within clinical settings that involve acute or disruptive symptom patterns, including Panic Disorder and Generalized Anxiety. It is relevant for easing symptom clusters that may become intense or disruptive, such as excessive sadness, loss of interest, and symptoms related to heightened physiological activity like sudden, intense fear.

“It is applied in addressing situations where functional stability becomes affected during the long-term management phase.”

Quick Fact: Support for Symptoms of Low Mood

Dalsan is relevant in conditions involving episodic or fluctuating manifestations. It supports the patient during difficult episodes by easing distress and assists with maintaining functional stability, contributing to improved day-to-day comfort during symptomatic periods.

Regulatory References

1. NIH MedlinePlus overview of Citalopram

Dalsan (citalopram) is approved for use only in adults 18 years of age and older. Use in children and adolescents under 18 is not approved as safety and effectiveness have not been established by regulatory authorities.

---

Absolute Contraindications (Must Not Use)

Official labeling strictly prohibits Dalsan use in patients with the following conditions or co-administered drugs:

• Monoamine Oxidase Inhibitors (MAOIs), including a 14-day washout period before and after treatment.
• Pimozide or any other medicinal products known to prolong the QT-interval.
• Congenital long QT syndrome or pre-existing QT interval prolongation.
• Known hypersensitivity to citalopram.

---

Conditional Use and Dose Restrictions

The risk of dose-dependent cardiac changes requires that certain populations use a maximum daily dose of 20 mg (half the general adult maximum). This restriction applies to older adults (typically age 60 or 65 and over), patients with hepatic impairment (liver problems), and those identified as CYP2C19 poor metabolizers.

Pregnancy and lactation are considered conditional restrictions, and the potential risks must be weighed carefully. Caution is advised, especially if used late in pregnancy.

Interactions with other medicines and products

Official regulatory documents define specific pharmacological and administrative restrictions for Dalsan (Citalopram) based on documented interaction patterns.

Contraindicated and Restricted Combinations

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is contraindicated due to the high risk of Serotonin Syndrome. A washout period of at least 14 days must separate the use of Dalsan and a psychiatric MAOI. The combination with Pimozide is also contraindicated, as Citalopram increases Pimozide exposure, posing a risk of QTc interval prolongation. This QTc risk extends to other medicinal products known to prolong the QT interval.

Pharmacodynamic and Metabolic Interactions

Concomitant use with other Serotonergic Medicinal Products (e.g., Triptans, Tramadol) is noted to increase the risk of Serotonin Syndrome. Interaction with drugs that interfere with hemostasis (e.g., NSAIDs, Warfarin) is documented to increase the official risk of hemorrhage. Citalopram is metabolized primarily by CYP enzymes, including CYP2C19. Inhibitors of this enzyme (e.g., Omeprazole) lead to decreased Citalopram clearance and increased systemic exposure. For CYP2C19 Poor Metabolizers and patients with Hepatic Impairment, this altered clearance requires a population-specific constraint. Use of Dalsan with the herbal product St. John's Wort is not recommended by regulatory authorities.

Selective Blockade of the Serotonin Transporter (SERT)

The primary action of Citalopram is the highly selective competitive inhibition of the Serotonin Transporter (SERT) on presynaptic nerve endings. By blocking this protein, the drug prevents the reabsorption of Serotonin (5-HT), immediately increasing its concentration and availability in the space between neurons. This mechanism initiates a subsequent change in central serotonergic signaling.

---

Time-Dependent Neuroadaptation and Synaptic Restructuring

The sustained increase in synaptic 5-HT triggers a slow, multi-week process of neuroadaptation, involving the downregulation and desensitization of specific serotonin receptors. This long-term cascade results in the modulation of neuroplasticity, including effects on Brain-Derived Neurotrophic Factor (BDNF), which is associated with neuronal growth and synaptic connectivity. This physiological restructuring of CNS pathways is the long-term consequence that alters central serotonergic signaling.

---

Enantiomeric Composition as a Mechanistic Constraint

Citalopram is a racemic mixture, containing both the active S-enantiomer and the less active R-enantiomer, which possesses some weak SERT affinity. The presence of the R-enantiomer, which possesses weak SERT affinity, introduces an internal interaction that alters the activity of the S-enantiomer’s reuptake inhibition.

How to Use Dalsan

This section outlines the general principles and official patterns for administering Dalsan (Citalopram), focusing strictly on administration protocol and prescribed dosing schedules.

---

Official Administration Guidelines

Dalsan is approved strictly for oral administration, utilizing either the film-coated tablet or the oral solution formulation. It is prescribed for once-daily intake and may be taken consistently with or without food. While the timing can be morning or evening, regularity is key to maintaining a consistent treatment level.

Treatment initiation for Major Depressive Disorder typically starts at 20 mg once daily for adults. The maximum daily dose for the general adult population is 40 mg, which dictates the upper limit of the maintenance regimen.

---

Population-Specific Constraints

Official labeling mandates specific dose restrictions for certain populations to maintain safe use patterns. The maximum daily dose must be restricted to 20 mg once daily for older adults (typically over 65 years of age) and for patients diagnosed with hepatic impairment (liver function issues). This 20 mg maximum also applies to individuals identified as CYP2C19 poor metabolizers due to expected differences in drug clearance. For patients with mild to moderate renal impairment, a dosage adjustment is generally not required.

---

Course Management Protocol

The protocol for using Dalsan is defined by dose titration and duration. The starting dosage should be reviewed within the first few weeks of administration. Treatment courses for depression often last for at least 6 months following the achievement of stability. Importantly, discontinuation of Dalsan must always involve a gradual reduction (tapering) of the dose over a period of time, as abrupt cessation is not an officially supported administration practice.

Research Evidence / Overview of Studies

---

Efficacy in Osteoarthritis (OA)

Research has explored whether the combination of the two active compounds affects pain and function in patients with knee osteoarthritis (OA).

• Meta-analysis Findings: A systematic review and meta-analysis of five randomized controlled trials (RCTs) examined the combined use of the two compounds. One meta-analysis evaluated whether taking the two ingredients together was associated with a reduction in pain over time.
• Comparison Studies: The studies also compared the combination to glucosamine or chondroitin alone.
• Specific Outcomes: The primary studies reviewed evaluated effects on reducing joint stiffness. Findings regarding improvements in joint function were mixed across the analyzed studies.

---

Research Focus on Biological Processes

Studies have explored the combination’s relationship with markers of inflammation and processes related to cartilage repair.

• Timeline of Observation: Studies have noted observation periods for reported findings ranging from approximately 4–12 weeks of continuous use.

---

Tolerability Profile in Studies

Clinical trials reported the combination’s tolerability profile.

• Common Adverse Events: The most frequently reported events in studies included mild gastrointestinal upset and headache.
• Other Data: It is not yet clear whether the compounds interact with blood-thinning medications.

Key Studies & References Glucosamine and Chondroitin for Osteoarthritis: What You Need To Know (NIH NCCIH Monograph)

Common questions about Dalsan (FAQ)

---

Q: Is Dalsan approved for long-term use?

Official guidelines for Major Depressive Disorder often recommend that treatment continue for at least six months following the achievement of stability. This duration is generally associated with efforts to stabilize treatment and reduce symptom recurrence. Dalsan may be taken for a longer duration as determined and prescribed by a healthcare provider.

---

Q: What is the time frame for Dalsan to start working?

Official information indicates that the full therapeutic effects of Dalsan may take between one to four weeks or longer to develop. This time is needed for the drug to create the required neurobiological changes in the central nervous system. However, some initial effects, such as improvements in sleep or energy levels, may be noted sooner.

---

Q: Can you take Dalsan with over-the-counter pain relievers like ibuprofen?

Official regulatory information documents that using Dalsan with medications that affect blood clotting, such as nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen, can increase the risk of bleeding or hemorrhage. This interaction occurs because both types of medicine can interfere with the body's natural blood clotting processes. Official documentation requires that all decisions regarding co-administered medications be made by a qualified healthcare professional.

---

Q: What is the risk of dependence or withdrawal with Dalsan?

The official product labeling warns against abruptly stopping Dalsan due to the potential for discontinuation symptoms, often referred to by users as withdrawal effects. These effects may include dizziness, sensory disturbances, or anxiety. Regulatory labeling indicates that discontinuation requires a gradual reduction of the dose, known as tapering, under medical supervision.

---

Q: Can Dalsan cause changes in mood or anxiety levels?

The drug label notes that Dalsan can cause some people to experience changes in mood and anxiety levels. These may include feelings of agitation, irritability, or increased anxiety. Regulatory warnings require that patients and caregivers closely observe behavior for these changes, including the appearance of manic episodes.

---

Q: What does the term 'contraindications' mean in relation to Dalsan?

A contraindication describes a clear and absolute circumstance where the use of the medicine is officially prohibited. In the context of Dalsan, contraindications relate to certain pre-existing conditions (e.g., congenital long QT syndrome) or co-administration with other medicines (e.g., MAOIs), as combining them creates a high or life-threatening risk.

---

Q: How long does the effect of a Dalsan dose typically last?

Dalsan is prescribed for once-daily dosing because the drug’s elimination half-life is documented to be approximately 35 hours. The half-life describes the time it takes for half of the drug to be eliminated from the body. This relatively long duration helps ensure a consistent therapeutic level is maintained in the system throughout the 24-hour period.

---

Q: Is Dalsan suitable for people with high blood pressure?

Official regulatory labeling does not list high blood pressure as an absolute contraindication for Dalsan use. However, cautions are given for individuals with underlying heart conditions or arrhythmia risk. Determining eligibility and risk management for individuals with heart health concerns is a decision made by the prescribing healthcare professional.

---

Q: Is Dalsan safe to take with alcohol?

Regulatory bodies strongly caution against the use of Dalsan with alcohol. This combination is known to increase certain side effects of the medicine, such as drowsiness or dizziness. Combining them may also interfere with the drug’s therapeutic goal by potentially worsening symptoms of depression and anxiety.

---

Q: What are the official guidelines regarding missing a dose of Dalsan?

Official guidelines state that if a dose of Dalsan is missed, it should be taken as soon as it is remembered. However, if the time is close to the next scheduled dose, the missed dose should be skipped entirely. The official protocol specifies that patients should not take a double dose to compensate for a missed dose.

---

Q: Is Dalsan known to cause weight gain or loss?

According to official safety information, Dalsan is known to cause changes in both weight and appetite. Both decreased and increased weight, as well as changes in appetite, are listed as common side effects, typically occurring in 1% to 10% of patients during clinical trials.

---

Q: Is Dalsan considered a controlled substance?

Dalsan (Citalopram) is not classified as a controlled substance by the U.S. Drug Enforcement Administration (DEA) or similar international bodies. This means that Dalsan is not scheduled under the federal Controlled Substances Act.

---

Q: What research evidence supports the use of Dalsan?

Official regulatory approval, such as the FDA's, is based on clinical trials that support the drug's efficacy for the treatment of Major Depressive Disorder (MDD) in adults. The drug’s position as a foundational SSRI means its role is established and included in essential medicine lists globally.

How to Store and Dispose of Dalsan?

The storage and disposal of Dalsan (Citalopram) must adhere strictly to regulatory requirements to ensure product stability and safety.

---

Official Storage Requirements

Storage Condition Type:	Controlled room temperature (20 C to 25 C / 68 F to 77 F)
Protection Constraints:	Protect from excessive heat and light (oral solution).
Container Rules:	Oral solution must be kept tightly closed in its original container.
Child-Safety Rule:	Keep out of the sight and reach of children.

---

Disposal Instructions

Outdated or unused Dalsan should be disposed of properly as defined by official guidance. It should not be flushed down a toilet or poured down a drain unless specifically instructed. Follow established protocols, which often involve mixing the product with an undesirable substance and placing it in a sealed container for household trash disposal when no drug take-back program is available.